Products - Liver cancers | Topic | NICE

Showing 11 products

Date | Title

Product type: GuidanceRemove ‘Product type: Guidance’ filter
New and updated: New in the last 6 monthsRemove ‘New and updated: New in the last 6 months’ filter

Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma (TA1090)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
19 August 2025
Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
17 July 2024
Suspected Cancer: recognition and referral (update)
Status:
In development
Programme:
NICE guideline
Expected publication date:
25 March 2026
Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
29 July 2026
Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver
Status:
In development
Programme:
Interventional procedures guidance
Expected publication date:
15 October 2026
Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
29 October 2026
Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab with or without bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6428]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Transarterial radio embolisation for osteosarcoma liver metastases
Status:
Topic prioritisation
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Tiragolumab with atezolizumab and bevacizumab for untreated unresectable or advanced hepatocellular carcinoma [TSID12238]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
CT hepatic arteriography for patients undergoing percutaneous ablation of primary or secondary liver tumours
Status:
Topic prioritisation
Programme:
Interventional procedures guidance
Expected publication date:
TBC